Skip to main contentSkip to navigation
Sirius Investors

UCB.BR Stock: UCB S.A. Stock Price, Analysis & Insights

Get live UCB.BR stock price $274.90, comprehensive UCB S.A. stock analysis, charts, news, and expert forecast. Real-time UCB.BR stock data and investment insights.

274.90
1.44%Today
UCB.BRUCB S.A. • Euronext Brussels • Healthcare
Market Cap
52.33B
Volume
169.04K
52W High
289.50
52W Low
153.65

Loading chart data...

UCB S.A. (UCB.BR) Overview

UCB S.A. (UCB.BR) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, UCB.BR trades at $274.90 with a market capitalization of 52.33B . Over the past 52 weeks, UCB.BR has traded between $153.65 and $289.50 , with the current price positioned at approximately 89% of this range . The stock currently trades at a...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 52.33B
  • Current price: $274.90
  • 52-week range: $153.65 - $289.50
  • P/E ratio: 34.19

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio incl...

Company Information

CEO
Jean-Christophe Tellier
Sector
Healthcare
Industry
Biotechnology
Employees
9052

Contact Information

Address
Allée de la Recherche, 60
Country
BE

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 34.2)

Lower volatility stock (Beta: 0.18) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for UCB S.A. shareholders
  • Market volatility can significantly impact stock price, especially for mid-cap stocks
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for UCB S.A.
  • Investors should consider how UCB S.A. fits within their overall portfolio allocation
  • Premium valuation (P/E: 34.2) requires strong growth to justify

Market Cap

52.33B

P/E Ratio (TTM)

34.19

Beta

0.18

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.